[go: up one dir, main page]

PE20130324A1 - Proteinas de fusion que comprenden un antigeno prame (dage) - Google Patents

Proteinas de fusion que comprenden un antigeno prame (dage)

Info

Publication number
PE20130324A1
PE20130324A1 PE2012001372A PE2012001372A PE20130324A1 PE 20130324 A1 PE20130324 A1 PE 20130324A1 PE 2012001372 A PE2012001372 A PE 2012001372A PE 2012001372 A PE2012001372 A PE 2012001372A PE 20130324 A1 PE20130324 A1 PE 20130324A1
Authority
PE
Peru
Prior art keywords
fusion protein
amino acids
protein
dage
fusion proteins
Prior art date
Application number
PE2012001372A
Other languages
English (en)
Inventor
Normand Blaise
Denis Martin
Remi M Palmantier
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39300029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0700760A external-priority patent/GB0700760D0/en
Priority claimed from GB0701262A external-priority patent/GB0701262D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20130324A1 publication Critical patent/PE20130324A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA PROTEINA DE FUSION QUE COMPRENDE: (a) UN PRAME O UN FRAGMENTO INMUNOLOGICO DEL MISMO QUE CONSTA DE UNO O MAS DE LOS EPITOPES SIGUIENTES: (i) VLDGLDVLL; (ii) SLYSFPEPEA ; ENTRE OTROS; (b) UNA PROTEINA PAREJA DE FUSION HETEROLOGA DERIVADA DE PROTEINA D QUE ESTA CONSTITUIDA POR LOS AMINOACIDOS 20 A 127 DE LA PROTEINA D Y LOS AMINOACIDOS LYS-21 Y LEU-22 ESTAN SUSTITUIDOS CON LOS AMINOACIDOS ASP-21 Y PRO-22; (C) UNA O MAS SECUENCIAS DE ENGARCE ENTRE LA PROTEINA FUSION Y EL ANTIGENO TUMORAL. REFERIDA ADEMAS A UN PROCEDIMIENTO Y A UNA VACUNA QUE CONTIENE UN COADYUVANTE TALES COMO 3D-MPL, QS21 Y/O OLIGONUCLEOTIDO CpG, Y/O UNA CITOQUINA O QUIMIOQUINA INMUNOESTIMULADORA. DICHA COMPOSICION QUE CONTIENE LA PROTEINA DE FUSION ES UTIL EN EL TRATAMIENTO DEL CANCER.
PE2012001372A 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage) PE20130324A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0700760A GB0700760D0 (en) 2007-01-15 2007-01-15 Vaccine
GB0701262A GB0701262D0 (en) 2007-01-23 2007-01-23 Vaccine

Publications (1)

Publication Number Publication Date
PE20130324A1 true PE20130324A1 (es) 2013-03-05

Family

ID=39300029

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008000124A PE20081686A1 (es) 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage)
PE2012001372A PE20130324A1 (es) 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008000124A PE20081686A1 (es) 2007-01-15 2008-01-11 Proteinas de fusion que comprenden un antigeno prame (dage)

Country Status (31)

Country Link
US (1) US20080187535A1 (es)
EP (1) EP2114993B1 (es)
JP (1) JP5391080B2 (es)
KR (1) KR20090101313A (es)
CN (1) CN101668770B (es)
AR (1) AR064862A1 (es)
AU (1) AU2008207025B2 (es)
BR (1) BRPI0806463A2 (es)
CA (1) CA2674552A1 (es)
CL (1) CL2008000104A1 (es)
CO (1) CO6210757A2 (es)
CR (1) CR10971A (es)
CY (1) CY1113760T1 (es)
DK (1) DK2114993T3 (es)
DO (1) DOP2009000167A (es)
EA (1) EA016326B1 (es)
ES (1) ES2393812T3 (es)
HR (1) HRP20120828T1 (es)
IL (1) IL199663A0 (es)
JO (1) JO2840B1 (es)
MA (1) MA31093B1 (es)
MX (1) MX2009007571A (es)
MY (1) MY153679A (es)
NZ (1) NZ578285A (es)
PE (2) PE20081686A1 (es)
PL (1) PL2114993T3 (es)
PT (1) PT2114993E (es)
SI (1) SI2114993T1 (es)
TW (1) TWI434697B (es)
WO (1) WO2008087102A1 (es)
ZA (1) ZA200904923B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089074A2 (en) * 2007-01-15 2008-07-24 Glaxosmithkline Biologicals Sa Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
CA2755734A1 (en) 2009-03-17 2010-09-23 Gaetan Otto Improved detection of gene expression
WO2010141953A2 (en) * 2009-06-05 2010-12-09 The Ohio State University Research Foundation Biomaterials, compositions, and methods
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
WO2013014105A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Biologicals S.A. Prame purification
GB201114919D0 (en) * 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
RU2590701C2 (ru) * 2013-04-29 2016-07-10 Общество с ограниченной ответственностью "ГеноТехнология" Антигенная композиция и ее терапевтическое применение для профилактики и лечения онкологических заболеваний, рекомбинантная плазмидная днк, обеспечивающая синтез гибридного белка, а также способ получения белка
EP3053592B1 (en) 2013-10-01 2025-04-23 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
CN105254767A (zh) * 2015-11-17 2016-01-20 重庆科润生物医药研发有限公司 一种Protein D与HER2融合蛋白及其制备方法和应用
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别源自于prame抗原短肽的tcr
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr及其相关组合物
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
CA3081710A1 (en) * 2017-11-08 2019-05-16 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
CN109879957B (zh) * 2017-12-06 2022-03-18 香雪生命科学技术（广东）有限公司 针对prame的高亲和力t细胞受体
WO2021243295A2 (en) * 2020-05-29 2021-12-02 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
IL308257A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Antigen binding proteins that uniquely bind PRAME

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE199316T1 (de) * 1993-12-23 2001-03-15 Bruno Gander Mit antigen beladene mikropartikel und pharmazeutische zubereitungen, die diese mikropartikel enthalten.
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
DK1584685T3 (da) * 1998-02-05 2011-07-11 Glaxosmithkline Biolog Sa Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
CA2376992A1 (en) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
CN1367875A (zh) * 1999-07-08 2002-09-04 斯特思吉生物技术公司 活体外th1一样反应的诱导方法

Also Published As

Publication number Publication date
EA016326B1 (ru) 2012-04-30
CO6210757A2 (es) 2010-10-20
US20080187535A1 (en) 2008-08-07
ES2393812T3 (es) 2012-12-28
AU2008207025B2 (en) 2012-08-23
DK2114993T3 (da) 2012-10-22
JP5391080B2 (ja) 2014-01-15
JO2840B1 (en) 2014-09-15
IL199663A0 (en) 2010-04-15
EP2114993B1 (en) 2012-08-29
TWI434697B (zh) 2014-04-21
MX2009007571A (es) 2009-07-22
KR20090101313A (ko) 2009-09-24
EA200900795A1 (ru) 2010-02-26
MY153679A (en) 2015-03-13
PL2114993T3 (pl) 2013-01-31
ZA200904923B (en) 2012-12-27
WO2008087102A1 (en) 2008-07-24
SI2114993T1 (sl) 2012-12-31
CA2674552A1 (en) 2008-07-24
HRP20120828T1 (hr) 2012-11-30
AR064862A1 (es) 2009-04-29
CR10971A (es) 2009-09-09
AU2008207025A1 (en) 2008-07-24
PT2114993E (pt) 2012-11-28
NZ578285A (en) 2011-12-22
DOP2009000167A (es) 2009-07-15
CL2008000104A1 (es) 2008-07-18
PE20081686A1 (es) 2008-12-25
HK1138853A1 (en) 2010-09-03
MA31093B1 (fr) 2010-01-04
EP2114993A1 (en) 2009-11-11
CY1113760T1 (el) 2016-07-27
CN101668770A (zh) 2010-03-10
BRPI0806463A2 (pt) 2011-09-06
CN101668770B (zh) 2013-06-12
JP2010515444A (ja) 2010-05-13
TW200902048A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
PE20130324A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
CL2024000411A1 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
AR112604A1 (es) Receptores de células t, e inmunoterapia usando los mismos
PE20200303A1 (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
MX374810B (es) Anticuerpos 4-1bb anti-humano y usos de los mismos
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
MX2010001088A (es) Composicion de peptidos asociados a tumor y vacunas relacionadas contra el cancer.
CO6420350A2 (es) Proteinas de union especificas y sus usos
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
PE20150605A1 (es) Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
CL2016001405A1 (es) A peptide mixture
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
CR20120026A (es) Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv
EA201071297A1 (ru) Новые и действенные пептиды мнс ii класса, полученные из сурвивина
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.

Legal Events

Date Code Title Description
FC Refusal